DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
EMICIZUMAB
Search structure
Trade Names:
HEMLIBRA
Synonyms:
ACE-910
ACE910
Emicizumab
Emicizumab-kxwh
Hemlibra
Status:
Approved (2017)
Entry Type:
Antibody
Molecule Category:
UNKNOWN
ATC:
B02BX06
UNII:
7NL2E3F6K3
Pharmacology
Action
Mechanism of Action
Reference
OTHER
Coagulation factor IX and X other
PubMed
PubMed
Indications
Mesh Heading
Maximum Phase
Mesh ID
Reference
Hemophilia A
4
D006467
FDA
Adverse Reactions
SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Injury, poisoning and procedural complications
18.92
Vascular disorders
18.92
General disorders and administration site conditions
13.51
Musculoskeletal and connective tissue disorders
13.51
Infections and infestations
4.89
Nervous system disorders
4.89
Investigations
4.05
Skin and subcutaneous tissue disorders
3.74
Respiratory, thoracic and mediastinal disorders
3.43
Gastrointestinal disorders
3.01
Cardiac disorders
2.6
Cross References
Resources
Reference
CAS NUMBER
1610943-06-0
ChEMBL
CHEMBL3833393
FDA SRS
7NL2E3F6K3
Guide to Pharmacology
9744
CONTENTS
Structure
Indications
Adverse Reactions
Cross References
×
Active Pharmaceutical Ingredients (APIs)
Scaffolds
Exact
Similarity
SubStructure
Threshold (%) >=
70